Skip to main content
SLU publication database (SLUpub)

Research article2021Peer reviewed

Polymeric antigen BLSOmp31 formulated with class B CpG-ODN in a nanostructure (BLSOmp31/CpG-ODN/Coa-ASC16) administered by parenteral or mucosal routes confers protection against Brucella ovis in Balb/c mice

Celeste Moran, Maria; Ricardo Bence, Angel; Sanchez Vallecillo, Maria Fernanda; Maria Lutzelschwab, Claudia; Gaston Rodriguez, Marcelo; Pardo, Romina; Alberto Goldbaum, Fernando; Zylberman, Vanesa; Daniel Palma, Santiago; Angelica Maletto, Belkys; Marcela Estein, Silvia

Abstract

Previously, we demonstrated that the chimera BLSOmp31 formulated in chitosan microspheres or Poloxamer407-Chitosan administered via the nasal and the ocular mucosa conferred partial protection in sheep against B. ovis. In this work, we tested a new delivery system for mucosal immunization with BLSOmp31 in the murine model to improve the efficacy of previously used formulations. First, we evaluated the protective efficacy against B. ovis induced by BLSOmp31 administered by the subcutaneous route using either BLSOmp31 alone, coadministered with immunostimulatory synthetic oligodeoxynucleotides containing unmethylated cytosineguanine motifs (CpG-ODN) or with CpG-ODN in a nanostructure called Coa-ASC16 compared with BLSOmp31 emulsified in Incomplete Freund Adjuvant. Then, we evaluated the protection conferred by the best performing formulation (BLSOmp31/CpG-ODN/Coa-ASC16) administered by both subcutaneous and ocular routes. BLSOmp31/CpG-ODN/Coa-ASC16 injected subcutaneously did not induce higher IgG antibody levels compared to BLSOmp31 alone or BLSOmp31/CpG-ODN but it did stimulate a mixed immune Th1-Th2 response with the highest levels of IFN-? and conferred significant protection against the B. ovis challenge. Although ocular instillation of BLSOmp31/CpG-ODN/Coa-ASC16 showed a similar degree of protection compared to the parenteral route (3.66 and 3.60 logs of protection, respectively), it induced lower levels in serum of specific IgG (with mixed IgG1/IgG2a) and IgA antibodies and, less IFN-? and IL-4 than the subcutaneous route. No antibodies were detected in vaginal lavages or saliva. Fecal antigen-specific IgA was slightly higher in mice immunized with BLSOmp31/CpG-ODN/Coa-ASC16 subcutaneously compared with the ocular route. These results indicate that BLSOmp31/CpG-ODN/Coa-ASC16 was a safe and effective vaccine against B. ovis in mice.

Keywords

BLSOmp31; CpG-ODN; Coa-ASC16; Experimental vaccine; Immune response; Brucella ovis; Protection; Murine model

Published in

Research in Veterinary Science
2021, Volume: 135, pages: 217-227
Publisher: ELSEVIER SCI LTD

    Sustainable Development Goals

    Ensure healthy lives and promote well-being for all at all ages

    UKÄ Subject classification

    Clinical Science

    Publication identifier

    DOI: https://doi.org/10.1016/j.rvsc.2021.02.011

    Permanent link to this page (URI)

    https://res.slu.se/id/publ/111443